Treatment of neuromyelitis optica: Review and recommendations

Treatment of neuromyelitis optica: Review and recommendations

Show other versions (1)

Neuromyelitis optica (NMO) is an autoimmune demyelinating disease preferentially targeting the optic nerves and spinal cord. Once regarded as a variant of multiple sclerosis (MS), NMO is now recognized to be a different disease with unique pathology and immunopathogenesis that does not respond to tr...

Bibliografske podrobnosti
Main Authors:	Kimbrough, D, Fujihara, K, Jacob, A, Lana-Peixoto, M, Isabel Leite, M, Levy, M, Marignier, R, Nakashima, I, Palace, J, De Seze, J, Stuve, O, Tenembaum, SN, Traboulsee, A, Waubant, E, Weinshenker, BG, Wingerchuk, D, Guthy Jackson Charitable Foundation Clinical Consortium and Biorepository
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2012

Podobne knjige/članki

Treatment of Neuromyelitis Optica: Review and Recommendations.
od: Kimbrough, D, et al.
Izdano: (2012)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
od: Jyh Yung Hor, et al.
Izdano: (2020-06-01)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Pittock, S, et al.
Izdano: (2019)

Neuroimmunology: towards more-accurate diagnosis in neuromyelitis optica.
od: Fujihara, K, et al.
Izdano: (2014)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
od: Collongues, N, et al.
Izdano: (2013)

The borderland of neuromyelitis optica.
od: Matthews, L, et al.
Izdano: (2009)

Neuromyelitis optica associated with systemic autoimmune diseases in children
od: Russo RA, et al.
Izdano: (2008-09-01)

Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
od: Mealy, M, et al.
Izdano: (2014)

Seronegative Neuromyelitis Optica Spectrum - The challenges on disease definition and pathogenesis
od: Douglas Kazutoshi Sato, et al.
Izdano: (2014-06-01)

Atypical presentations of neuromyelitis optica
od: Douglas Sato, et al.
Izdano: (2011-10-01)

Influence of pregnancy on neuromyelitis optica spectrum disorder.
od: Kim, W, et al.
Izdano: (2012)

Use of mitoxantrone in neuromyelitis optica.
od: Kitley, J, et al.
Izdano: (2011)

Current and future treatment approaches for neuromyelitis optica
od: Nicolas Collongues, et al.
Izdano: (2011-03-01)

Treatment of neuromyelitis optica: an evidence based review
od: Douglas Sato, et al.
Izdano: (2012-01-01)

Differential diagnosis of neuromyelitis optica spectrum disorders
od: Sung-Min Kim, et al.
Izdano: (2017-07-01)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
od: Nour, M, et al.
Izdano: (2014)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
od: Elsone, L, et al.
Izdano: (2012)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
od: Waters, P, et al.
Izdano: (2015)

Magnetic resonance imaging in neuromyelitis optica.
od: Tackley, G, et al.
Izdano: (2014)

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica
od: Nicolas Collongues, et al.
Izdano: (2016-05-01)

Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort
od: Shervin Gholizadeh, et al.
Izdano: (2024-10-01)

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
od: Cree, BAC, et al.
Izdano: (2019)

A practical guide to the treatment of neuromyelitis optica.
od: Palace, J, et al.
Izdano: (2012)

The evolving clinical spectrum of neuromyelitis optica
od: Viegas, S, et al.
Izdano: (2008)

A mathematical model of cellular swelling in Neuromyelitis optica
od: Laranjeira, S, et al.
Izdano: (2017)

Anti-MOG Antibodies in Japanese Patients with Neuromyelitis Optica Spectrum Disorders
od: Sato, D, et al.
Izdano: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, et al.
Izdano: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, et al.
Izdano: (2013)

Neuromyelitis Optica
od: Goyal V, et al.
Izdano: (2009-10-01)

Neuromyelitis optica
od: Jacob Anu, et al.
Izdano: (2007-01-01)

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Nour, M, et al.
Izdano: (2015)

Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis.
od: Lucy Matthews, et al.
Izdano: (2015-01-01)

Anti-aquaporin-4 antibodies in Devic’s neuromyelitis optica: therapeutic implications
od: Romain Marignier, et al.
Izdano: (2010-09-01)

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
od: Viegas, S, et al.
Izdano: (2009)

Seasonal pattern of variation in neuromyelitis optica relapses
od: Elsone, L, et al.
Izdano: (2012)

NMO-IgG in the diagnosis of neuromyelitis optica.
od: Jarius, S, et al.
Izdano: (2007)

NEUROMYELITIS OPTICA IN SOUTH WALES AND THE SOUTH WEST OF ENGLAND
od: Luppe, S, et al.
Izdano: (2012)

Case Report: In Situ Expression of a Proliferation-Inducing Ligand in Neuromyelitis Optica
od: Laurie Baert, et al.
Izdano: (2021-08-01)

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder
od: Achim Berthele, et al.
Izdano: (2023-04-01)

Racial differences in neuromyelitis optica spectrum disorder
od: Kim, S, et al.
Izdano: (2018)